Patent Ductus Arteriosus After Premature Birth Clinical Trial
Official title:
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants - The ACEDUCT Trial
Patent ductus arteriosus (PDA), the most common cardiovascular complication of prematurity, is associated with higher mortality and morbidities in extremely low gestational age neonates (ELGANs, < 27+0 weeks). Ibuprofen and acetaminophen, which act by reducing prostaglandin synthesis, are the most commonly used first and second line agents for PDA treatment across Canada. However, initial treatment failure with monotherapy is a major problem, occurring in >60% ELGANs. Treatment failure is associated with worsening rates of mortality and bronchopulmonary dysplasia (BPD), while early treatment success can achieve rates comparable to neonates without PDA. Treatment failure resulting in prolonged disease exposure is thought to be a major contributor. Recently, combination therapy with acetaminophen and ibuprofen has emerged as a new treatment regime. Acetaminophen exerts anti-prostaglandin effect through a different receptor site than ibuprofen, providing a biological rationale for their synergistic action. The objective of this study is to evaluate the clinical impact, efficacy and safety of combination regime (Ibuprofen + IV Acetaminophen) for the first treatment course for PDA in ELGANs vs. Ibuprofen alone (current standard treatment).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04126512 -
Timing of Surgical PDA Ligation and Neonatal Outcomes
|
||
| Recruiting |
NCT04359134 -
Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.
|
||
| Recruiting |
NCT05325177 -
PDA Treatment With Ibuprofen and Changes in Tissue Oxygenation.
|
Phase 4 | |
| Active, not recruiting |
NCT03675425 -
The Effects of Phototherapy in Preterm Infants Pda
|
N/A | |
| Recruiting |
NCT04037514 -
Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus
|
Phase 3 | |
| Recruiting |
NCT05686343 -
Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks
|
||
| Withdrawn |
NCT04025177 -
Indomethacin PK-PD in Extremely Preterm Neonates
|
Phase 2 | |
| Recruiting |
NCT05011149 -
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
|
Phase 3 | |
| Recruiting |
NCT03456336 -
Management of the PDA Trial
|
Phase 3 | |
| Completed |
NCT05493540 -
Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants
|
Phase 2 |